mTORC1 promotes survival through translational control of Mcl-1
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E μ- myc murine lymphoma model leads to mTORC1 activation and accelerated oncogenesis caused by a defective apoptotic program despite compromised AKT phosphorylation. Tumors from Tsc2 +/− E μ- Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin. We identified myeloid cell leukemia sequence 1 ( Mcl-1 ), a bcl-2 like family member, as a translationally regulated genetic determinant of mTORC1-dependent survival. Our results indicate that the extent by which rapamycin can modulate expression of Mcl-1 is an important feature of the rapamycin response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TORC1 inhibition, via loss of 4EBP1 (also referred to as EIF4EBP1) phosphorylation, results in a decrease of MCL-1 protein expression in these cancers (37–40).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous studies had demonstrated that efficient translation of MCL-1 mRNA requires cap-dependent translation in some cancers (36–38).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citation
Cited by
Mackay, F., & Schneider, P. (2009) · Nature Reviews Immunology · doi:10.1038/nri2572 · Cited by 930
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
“Mcl-1 has also been reported to be a translationally regulated gene, and its expression is affected by eIF4E phosphorylation in primary fibroblasts and tumors associated with loss of Tsc2 (tuberous sclerosis 2 protein) (Mills et al., 2008).”
Translational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
“2) (Koromilas et al. 1992a; Stoneley and Willis 2003; Pickering and Willis 2005; Ruggero and Sonenberg 2005; Mills et al. 2008; Hsieh et al. 2010).”
BackgroundCommon corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
“Translation of the pro-survival Bcl-2 family member MCL-1 can be stimulated by mTORC1 activity, and this mechanism has been shown to contribute to cell survival in a mouse lymphoma model (Mills et al., 2008).”
BackgroundMcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319
Self-citationAntitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
“Yet, altering eIF4E levels by transcriptional activation [44], knock down using shRNAs [44], or inhibiting mTOR activity [45] in transformed cells can affect mRNA-selective translation and global rates of protein synthesis (,2-fold decrease).”
BackgroundMethodSelf-citationApoptosis and oncogenesis: give and take in the BCL-2 family
Llambi, F., & Green, D. R. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.12.001 · Cited by 262
“Phosphorylation of MCL-1 by GSK3 links its ubiquitinylation by β-TrCP and half-life to growth factor signaling [61], while translational control of MCL-1 is similarly linked by the TORC1 complex [62]•, resulting in decreased MCL-1 upon growth factor deprivation.”
BackgroundDecoding and unlocking the BCL-2 dependency of cancer cells
Juin, P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3538 · Cited by 232
Regulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S. A., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 216
“Mcl-1 is a short-lived protein, positively regulated by the mTOR signaling pathway, while negatively by the E3 ligases Mcl-1 ubiquitin ligase E3 (Mule), F-Box and WD repeat domain containing 7 (Fbw7), Tripartite motif containing 17 (Trim17) and β-transducin repeat containing E3 ubiquitin protein ligase 1 (β-TrCP1), th…”
BackgroundmTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., & Shaw, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900465106 · Cited by 205
Martelli, A. M., Evangelisti, C., Chappell, W., Abrams, S. L., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.46 · Cited by 204
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F
Cencic, R., Hall, D. R., Robert, F., Du, Y., Min, J., Li, L., Qui, M., Lewis, I., Kurtkaya, S., Dingledine, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011477108 · Cited by 185
“4C), and decreased levels of Mcl-1 and c-Myc proteins, two eIF4E-dependent mRNAs (19, 20) (Fig.”
BackgroundInfluentialSelf-citationCancer Metabolism and the Evasion of Apoptotic Cell Death
Sharma, A., Boise, L., & Shanmugam, M. (2019) · Cancers · doi:10.3390/cancers11081144 · Cited by 185
“The inability to effectively target BCL-2 proteins accounts for resistance to bortezomib [153–155], rapamycin [156], cyclin-dependent kinase inhibitors [157], ABT 737 [158], and death receptor (Fas/TRAIL)-induced apoptosis [106] in various cancers including MM.”
BackgroundMackay, F., Figgett, W. A., Saulep, D., Lepage, M., & Hibbs, M. L. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00944.x · Cited by 182
“When mTORC1 was inactivated by deletion of its positive regulator tuberous sclerosis protein 2 (TSC2), B-cell tumors failed to grow due to lack of Mcl-1 expression (131).”
BackgroundMcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein
Mojsa, B., Lassot, I., & Desagher, S. (2014) · Cells · doi:10.3390/cells3020418 · Cited by 181
Apoptosis in Cancer Biology and Therapy
Moyer, A., Tanaka, K., & Cheng, E. H. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 173
McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171
“Moreover, HIF-1a regulates the glycolytic pathway by controlling the expression of glucosesensing molecules including glucose transporter (Glut) 1 and Glut3 (Mobasheri et al., 2005).”
BackgroundMechanisms of mTOR inhibitor resistance in cancer therapy
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161
“Induction of apoptosis by rapalogs may be related to their ability to decrease the expression levels of various anti-apoptotic proteins, including Bcl-2, Bcl-xL, Mcl-1, and survivin [28, 92–95].”
BackgroundOng, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162
“It was further demonstrated to be specifically mediated through mTORC1 via increased translation of anti-apoptotic Mcl-1 protein (Mills et al., 2008).”
BackgroundMCL‐1 is a stress sensor that regulates autophagy in a developmentally regulated manner
Germain, M., Nguyen, A. P., Le Grand, J. N., Arbour, N., Vanderluit, J. L., Park, D. S., Opferman, J. T., & Slack, R. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.327 · Cited by 159
“More recently, MCL-1 transcription has been shown to be regulated by mTOR, the key regulator of transcription that is inactivated following nutrient starvation (Mills et al, 2008; Pradelli et al, 2010).”
BackgroundSaga of Mcl-1: regulation from transcription to degradation
Senichkin, V. V., Streletskaia, A. Y., Gorbunova, A. S., Zhivotovsky, B., & Kopeina, G. S. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0486-3 · Cited by 155
“Perhaps a more selective way to control Mcl-1 synthesis is the regulation of cap-dependent translation (CDT), a common translational mechanism controlled by the eIF4F protein complex, the assembly of which is positively regulated by the mammalian target of rapamycin complex 1 (mTORC1). eIF4F availability differently i…”
BackgroundCotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
Rahmani, M., Nkwocha, J., Hawkins, E., Pei, X., Parker, R. E., Kmieciak, M., Leverson, J. D., Sampath, D., Ferreira-Gonzalez, A., & Grant, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3024 · Cited by 145
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
Zhang, S., Zhang, M., Jing, Y., Yin, X., Ma, P., Zhang, Z., Wang, X., Di, W., & Zhuang, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02693-9 · Cited by 144
Pradelli, L. A., Bénéteau, M., Chauvin, C., Jacquin, M. A., Marchetti, S., Muñoz‐Pinedo, C., Auberger, P., Pende, M., & Ricci, J. (2009) · Oncogene · doi:10.1038/onc.2009.448 · Cited by 167
“50 untranslated region (Mills et al., 2008) and (ii) given that Mcl-1 protein is highly regulated and rapidly degraded (Zhong et al., 2005; Maurer et al., 2006), inhibition of its synthesis would lead to a major decrease in protein level.”
BackgroundTargeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Dalva-Aydemir, S., Bajpai, R., Martinez, M., Adekola, K. U. A., Kandela, I., Wei, C., Singhal, S., Koblinski, J. E., Raje, N. S., Rosen, S. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1088 · Cited by 142
“MCL-1 is particularly important in the development of resistance, as the inability to decrease MCL-1 expression correlates to resistance to bortezomib (31), rapamycin (32), cyclin-dependent kinase inhibitors (33), and the BCL-2/BCL-XL/BCL-w selective antagonist ABT 737 (34) in multiple myeloma and various cancers.”
BackgroundColoff, J. L., Macintyre, A. N., Nichols, A., Liu, T., Gallo, C. A., Plas, D. R., & Rathmell, J. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4531 · Cited by 151
“regulated through transcriptional mechanisms induced by cytokines including interleukin (IL)-2, -3, and -7, as well as by control of protein translation throughmTOR (14, 23).”
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 142
“, 2015), as does downregulation of p-4EBP1, which mediates eIF4 complex formation and subsequent cap-dependent translation (Faber et al., 2014, 2015; Hsieh et al., 2010; Mallya et al., 2014; Mills et al., 2008; Schatz et al., 2011).”
BackgroundInfluentialS6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., & Karni, R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.020 · Cited by 129
“One such protein is Mcl-1 (Hsieh et al., 2010), a key antiapoptotic protein that was shown to be translationaly controlled by mTORC1 (Mills et al., 2008).”
BackgroundFaber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Li, X.-J., Luo, X.-Q., Han, B.-W., Duan, F.-T., Wei, P.-P., & Chen, Y.-Q. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.562 · Cited by 127
“In a murine lymphoma model, Mills et al, reported that MCL1 down-regulation is dependent on the inhibition of the mTOR complex 1 (mTORC1), which has the classic features of mTOR (Mills et al, 2008).”
BackgroundFaber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Kumar, S., Sharife, H., Kreisel, T., Mogilevsky, M., Bar-Lev, L., Grunewald, M., Aizenshtein, E., Karni, R., Paldor, I., Shlomi, T., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.003 · Cited by 121
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
Xiang, Z., Luo, H., Payton, J. E., Cain, J., Ley, T. J., Opferman, J. T., & Tomasson, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39964 · Cited by 118
A cellular response linking eIF4AI activity to eIF4AII transcription
Galicia-Vázquez, G., Cencic, R., Robert, F., Agenor, A. Q., & Pelletier, J. (2012) · RNA · doi:10.1261/rna.033209.112 · Cited by 119
“1B), a line genetically engineered to have higher mTORC1 activity (Mills et al. 2008).”
BackgroundInfluentialSelf-citationSchatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110846 · Cited by 119
“Eµ-Myc/Tsc2/ lym phomas are generated by crossing Eµ-Myc+/ mice to Tsc2+/ mice (Mills et al., 2008).”
BackgroundSelf-citationWilliams, M. M., & Cook, R. S. (2015) · Oncotarget · doi:10.18632/oncotarget.2792 · Cited by 137
“However, unlike other Bcl-2 family members, Mcl-1 has a short half-life and is highly regulated at the transcriptional, post-transcriptional, translational and post-translational levels [55, 56] by various oncogenic signaling pathways (Figure 2), including the mitogen activated protein kinase (MAPK) pathway [57], the…”
BackgroundBojarczuk, K., Sasi, B. K., Gobessi, S., Innocenti, I., Pozzato, G., Laurenti, L., & Efremov, D. G. (2016) · Blood · doi:10.1182/blood-2015-10-675009 · Cited by 123
The cancerous translation apparatus
Stumpf, C. R., & Ruggero, D. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.03.007 · Cited by 116
“One example is Mcl-1, an anti-apoptotic factor containing a complex 50UTR that is specifically translationally upregulated upon eIF4E hyperactivation leading to enhanced survival of cancer initiating cells [34,36].”
BackgroundAttacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members
Opferman, J. T. (2016) · The FEBS Journal · doi:10.1111/febs.13472 · Cited by 113
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Brown, K. K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 111
“Themechanisms that contribute to chemotherapy resistance downstream of PI3K signaling are diverse; however, the elevated expression of anti-apoptotic proteins, includingmyeloid cell leukemia 1 (Mcl-1), is frequently observed [11,12].”
BackgroundAkt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue
Miyamoto, S., Murphy, A. N., & Brown, J. H. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9205-y · Cited by 104
“In addition to the potential for control of Mcl-1 protein stability through Akt/GSK-3β, Mcl-1 is transcriptionally up-regulated in response to Akt activation through mTOR signaling and promotes tumor cell survival (Mills et al. 2008).”
BackgroundBajpai, R., Matulis, S. M., Wei, C., Nooka, A. K., Hollen, H. V., Lonial, S., Boise, L., & Shanmugam, M. (2015) · Oncogene · doi:10.1038/onc.2015.464 · Cited by 110
Understanding MCL1: from cellular function and regulation to pharmacological inhibition
Sancho, M., Leiva, D., Lucendo, E., & Orzáez, M. (2021) · FEBS Journal · doi:10.1111/febs.16136 · Cited by 118
Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?
Thomas, A., Kelly, G. L., & Strasser, A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00996-z · Cited by 110
“Loss of Trp53 prevented mutant RAS induced cell senescence in mouse models, thereby promoting tumorigenesis [64, 65].”
BackgroundInfluentialGores, G. J., & Kaufmann, S. H. (2012) · Genes & Development · doi:10.1101/gad.186189.111 · Cited by 99
“2007), whereas activation of themammalian target of rapamycin complex 1 (mTORC1) enhances translation and promotes tumor cell survival by increasing Mcl-1 levels (Mills et al. 2008).”
BackgroundLi, L. Q., Pongtornpipat, P., Tiutan, T., Kendrick, S. L., Park, S., Persky, D. O., Rimsza, L. M., Puvvada, S. D., & Schatz, J. H. (2015) · Leukemia · doi:10.1038/leu.2015.99 · Cited by 105
Yue, W., Zheng, X., Lin, Y., Yang, C. S., Xu, Q., Carpizo, D. R., Huang, H., DiPaola, R. S., & Tan, X. (2015) · Oncotarget · doi:10.18632/oncotarget.4126 · Cited by 103
“The mTOR signaling pathway has been reported to regulate Mcl-1 at both transcriptional and translational levels [48, 50].”
Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Lin, C.-J., Nasr, Z., Premsrirut, P. K., Porco, J. A., Hippo, Y., Lowe, S. W., & Pelletier, J. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.010 · Cited by 90
“…displaying overt cytotoxicity to nontransformed cells, As well, Myc lymphoma cells expressing shRNAs to eIF4E have a selective growth disadvantage (Mills et al., 2008), over-expression of eIF4E antagonizes Myc-dependent apoptosis (Li et al., 2003; Ruggero et al., 2004), and gene amplification…”
BackgroundSelf-citationAltering chemosensitivity by modulating translation elongation
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005428 · Cited by 90
“For this purpose, we used Tsc2 Em-Myc lymphomas cultured ex vivo [20].”
BackgroundMethodSelf-citationT and B‐cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity
Preite, S., Gómez‐Rodríguez, J., Cannons, J. L., & Schwartzberg, P. L. (2019) · Immunological Reviews · doi:10.1111/imr.12790 · Cited by 91
Size control: the developmental physiology of body and organ size regulation
Gokhale, R. H., & Shingleton, A. W. (2015) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.181 · Cited by 106
Wang, R., Xia, L., Gabrilove, J., Waxman, S., & Jing, Y. (2013) · Leukemia · doi:10.1038/leu.2012.180 · Cited by 85
“HL-60 cells were developed from an APL patient without the t(15;17) translocation and are considered a non-APL AML cell line (23).”
BackgroundInfluentialRegulation of Mcl-1 by SRSF1 and SRSF5 in Cancer Cells
Gautrey, H., & Tyson-Capper, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051497 · Cited by 98
“Additionally, Mcl-1 has also been shown to be translationally controlled by mTOR and the mTOR signalling pathway [24,25,26,27,28].”
BackgroundResultImpact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
Ho, A. L., Musi, E., Ambrosini, G., Nair, J. S., Vasudeva, S. D., de Stanchina, E., & Schwartz, G. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040439 · Cited by 88
“mTOR has been shown to stimulate cell survival by promoting expression of myeloid leukemia sequence-1 (MCL-1), a prosurvival member of the bcl-2 family of genes [26].”
BackgroundWang, B., Ni, Z., Dai, X., Qin, L., Li, X., Xu, L., Lian, J., & He, F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-98 · Cited by 88
“Meanwhile, phosphorylation of mammalian target of rapamycin (mTOR) was also detected upon ABT-263 treatment since its activation through phosphorylation can regulate the translational process of Mcl-1 protein [23].”
BackgroundOncogenic AKTivation of translation as a therapeutic target
Hsieh, A. C., Truitt, M., & Ruggero, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.241 · Cited by 84
“British Journal of Cancer (2011) 105, 329–336. doi:10.1038/bjc.2011.241 www.bjcancer.com Published online 19 July 2011 & 2011 Cancer Research UK Keywords: AKT; eIF4E; translational control; ribosome; PI3K; mTOR”
BackgroundInfluentialEfremov, D. G., Turkalj, S., & Laurenti, L. (2020) · Cancers · doi:10.3390/cancers12061396 · Cited by 92
“Notably, prolonged AKT activity results in increased mTORC1 and reduced GSK3 activity, with a resulting increase in Mcl-1 protein translation and inhibition of MCL1 degradation, respectively [54,56,57].”
BackgroundYi, Y. W., Hong, W., Kang, H. J., Kim, H. J., Zhao, W., Wang, A., Seong, Y., & Bae, I. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12046 · Cited by 84
“In addition, the level of myeloid cell leukemia 1 (Mcl-1) protein was markedly decreased by gefitinib/PI-103 combination in the BL TNBC cells, but showed no significant change by this combination in MSL subtype cells.”
BackgroundInfluentialZhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., Cawley, J. C., & Pettitt, A. R. (2009) · Haematologica · doi:10.3324/haematol.2009.010272 · Cited by 87
“For example, Akt indirectly activates mTORC1,(14) thereby promoting translation of MCL1 through a GSK-3-independent mechanism.(18) This may explain why, in the present study, the GSK-3 inhibitor employed did not completely abrogate the loss of”
BackgroundLang, J.-Y., Hsu, J. L., Meric‐Bernstam, F., Chang, C.-J., Wang, Q., Bao, Y., Yamaguchi, H., Xie, X., Woodward, W. A., Yu, D., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.017 · Cited by 83
“…Cell 20, 341–356, September 13, 2011 ª2011 Elsevier Inc. initiation and progression, enabling cancer cells to undergo unchecked proliferation, maintain survival, and acquire drug resistance (Datta et al., 1999; Fesik, 2005; Hanahan and Weinberg, 2000; McCubrey et al., 2006; Mills et al., 2008).”
EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival
Fu, N. Y., Rios, A. C., Pal, B., Soetanto, R., Lun, A. T. L., Liu, K., Beck, T. J., Best, S. A., Vaillant, F., Bouillet, P., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3117 · Cited by 91
Arai, S., Jonas, O., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 74
“PI3K pathway inhibition may enhance apoptosis through multiple mechanisms, and particularly may decrease MCL1 translation through suppression ofmTORC1 and increased MCL1 degradation through activation of GSK3b (25, 26).”
BackgroundInfluentialSelf-citationNuclear and mitochondrial signalling Akts in cardiomyocytes
Miyamoto, S., Rubio, M., & Sussman, M. A. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvp087 · Cited by 80
Shortt, J., Martin, B. P., Newbold, A., Hannan, K. M., Devlin, J. R., Baker, A. J., Ralli, R., Cullinane, C. M., Schmitt, C. A., Reimann, M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-446096 · Cited by 74
Programming cancer cells for high expression levels of Mcl1
Ertel, F., Nguyen, M., Roulston, A., & Shore, G. C. (2013) · EMBO Reports · doi:10.1038/embor.2013.20 · Cited by 75
“Accelerated oncogenesis caused by mTorc1 activation in a murine model of lymphomagenesis, for example, was accompanied by translational maintenance of Mcl1 [84].”
Nogami, A., Oshikawa, G., Okada, K., Fukutake, S., Umezawa, Y., Nagao, T., Kurosu, T., & Miura, O. (2015) · Oncotarget · doi:10.18632/oncotarget.3279 · Cited by 69
“The translation of Mcl-1 mRNA, with a lengthy G+C-rich 5′ UTR, is mainly regulated by formation of the eIF4F complex [20, 21], which plays a critical role in cap-dependent translation and is directly competed by hypophosphorylated 4EBP1 induced by suppression of the mTOR pathway [18, 22].”
BackgroundModifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A
Cencic, R., Robert, F., Galicia-Vázquez, G., Malina, A., Ravindar, K., Somaiah, R., Pierre, P., Tanaka, J., Deslongchamps, P., & Pelletier, J. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.25 · Cited by 66
Self-citationNiessner, H., Beck, D., Sinnberg, T. W., Lasithiotakis, K. G., Maczey, E., Gogel, J., Venturelli, S., Berger, A., Mauthe, M., Toulany, M., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.297 · Cited by 67
“, 2005), and mTOR has been demonstrated to promote survival through translational control of Mcl-1 (Mills et al., 2008).”
BackgroundLin, C., Malina, A., & Pelletier, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0813 · Cited by 73
“We have previously found that Tsc2 El-Myc lymphomas arise much more rapidly as consequence of constitutively active mTOR activity and are sensitive to rapamycin treatment (23).”
BackgroundSelf-citationEkholm-Reed, S., Goldberg, M. S., Schlossmacher, M. G., & Reed, S. I. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00535-13 · Cited by 66
“However, Mcl-1 has been reported to be regulated at the level of translation by the mTORC1 pathway (65).”
BackgroundWang, L., Wang, J., Xiong, H., Wu, F., Lan, T., Zhang, Y., Guo, X., Wang, H., Saleem, M., Jiang, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.022 · Cited by 67
“3E and data not shown), consistent with previous observation that MCL-1 can be translationally regulated by mTOR signaling in certain cancer cells (Mills et al., 2008).”
Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 63
“In cap-dependent translation, the mTORC1 complex phosphorylates 4E-BP1, resulting in 4E-BP1 sequestration away from eIF4E, promoting the binding of eIF4E to eIF4G and assembly of the eIF4F complex: in cancers in which this pathway is perpetually active, dependence develops on short-lived oncogenes, such as MCL-1 (20,…”
BackgroundEmerging Therapeutics Targeting mRNA Translation
Malina, A., Mills, J. R., & Pelletier, J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012377 · Cited by 65
“1B) (Wendel et al. 2004, 2006; Mills et al. 2008).”
BackgroundSelf-citationWall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Self-citationmTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 69
Interplay between protein acetylation and ubiquitination controls MCL1 protein stability
Shimizu, K., Gi, M., Suzuki, S., North, B. J., Watahiki, A., Fukumoto, S., Asara, J. M., Tokunaga, F., Wei, W., & Inuzuka, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109988 · Cited by 62
“…growth factors and cytokines induce MCL1 gene expression (Thomas et al., 2010), multiple microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) control the stability of MCL1 mRNA (Cui and Placzek, 2018; Senichkin et al., 2020), and mTORC1 promotes MCL1 protein translation (Mills et al., 2008).”
AKT kinases as therapeutic targets
Hassan, D., Menges, C. W., Testa, J. R., & Bellacosa, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03207-4 · Cited by 82
“…can be caused by TSC1/2 loss, which activates mTORC1 and blocks apoptosis in a BAK-dependent manner, even with a reduced level of phosphorylated AKT, possibly by mTORC1-mediated translational control of Mcl-1, and can be overcome by combining AKT inhibitors with an Mcl-1 inhibitor [332, 333].”
Yang, J.-M., Hung, C., Fu, C.-N., Lee, J., Huang, C.-H., Yang, M., Lin, C., Kao, J., & Way, T. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf102304g · Cited by 63
Self-citationCaloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice
Meynet, O., Zunino, B., Happo, L., Pradelli, L. A., Chiche, J., Jacquin, M. A., Mondragón, L., Tanti, J., Taillan, B., Garnier, G., et al. (2013) · Blood · doi:10.1182/blood-2013-01-478651 · Cited by 68
Targeting Translation Dependence in Cancer
Malina, A., Cencic, R., & Pelletier, J. (2011) · Oncotarget · doi:10.18632/oncotarget.218 · Cited by 66
“Thus, cancers driven by hyperactive mTOR signaling would be hypersensitive to treatment with rapamycin, and this is often the case in cell culture [100] and mouse models [98, 101].”
BackgroundSelf-citationMelnik, B. C. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150114100653 · Cited by 63
“In non-obese diabetic (NOD) mice, upregulation of microRNA- 29a, b, and c caused pancreatic -cell death via suppression of Mcl-1, an essential member of the pro-survival Bcl-2 fam- ily genes [227].”
BackgroundInfluentialJebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 66
“First, it promotes Mcl-1 expression at different levels: (i) transcriptional, via the activation of CREB transcription factor [21]; (ii) translational, via the activation of mTORC1 and subsequent phosphorylation of 4E-BP1 [22,23]; and (iii) post-translational, through decreased proteasomal degradation due to repressio…”
BackgroundGrowth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway
Schmidt, E. V., Ravitz, M. J., Chen, L., & Lynch, M. C. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8215 · Cited by 57
Yun, S., Vincelette, N. D., Knorr, K. L. B., Almada, L. L., Schneider, P. A., Peterson, K. L., Flatten, K. S., Dai, H., Pratz, K. W., Hess, A. D., et al. (2016) · Blood · doi:10.1182/blood-2015-02-629485 · Cited by 58
Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells
Li, B., Li, X., Ni, Z., Zhang, Y., Zeng, Y., Yan, X., Huang, Y., He, J., Lyu, X., Wu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10694 · Cited by 55
“It has been reported activation of mTOR promotes Mcl-1 translation [26], so we analyzed p-mTOR after cotreatment with Met and DCA.”
MethodAnderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0348 · Cited by 53
Koo, J., Yue, P., Deng, X., Khuri, F. R., & Sun, S. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01525-14 · Cited by 53
“translation, which contributes to mTORC1-dependent survival (8).”
BackgroundCheng, L., Cheng, L., Bi, H.-E., Zhang, Z.-Q., Yao, J., Zhou, X., & Jiang, Q. L. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.113 · Cited by 53
“These results are not surprising, since mTORC1 is proposed as an important survival factor [6,39].”
BackgroundBommer, U., Vine, K. L., Puri, P., Engel, M., Belfiore, L., Fildes, K. J., Batterham, M. J., Lochhead, A., & Aghmesheh, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0164-3 · Cited by 53
“Examples are the proteins Bcl-2 and Bcl-XL [74], Mcl-1 [75, 76], and survivin, which was shown to be important for promoting motility and metastasis in CRC via translational control mechanisms [77].”
BackgroundAdekola, K., Dalva-Aydemir, S., Ma, S., Zhou, Z. G., Rosen, S. T., & Shanmugam, M. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.922180 · Cited by 54
“The inability to decrease expression of the pro-survival BCL-2 family member, Mcl-1 correlates with resistance to bortezomib 35 , rapamycin 36 , cyclin-dependent kinase inhibitors 37 , the Bcl-2/Bcl-XL/Bcl-w selective antagonist ABT 737 38 and death receptor (Fas/TRAIL) 39 -induced apoptosis in…”
BackgroundGILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
Joha, S., Nugues, A.-L., Hétuin, D., Berthon, C., Dezitter, X., Dauphin, V., Mahon, F., Roche‐Lestienne, C., Preudhomme, C., Quesnel, B., et al. (2011) · Oncogene · doi:10.1038/onc.2011.328 · Cited by 57
“These results suggest that GILZ alone does not interfere with the PDK1/AKT/mTORC1 pathway or with the MEK/ERK pathway (Wang et al., 2005; Mills et al., 2008; Ikenoue et al., 2009).”
Kontham, R., Reddy, M. S., Lindqvist, L., Pelletier, J., & Deslongchamps, P. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo102054r · Cited by 51
Self-citationZhang, C., Ryu, Y., Chen, T. Z., Hall, C. P., Webster, D. R., & Kang, M. H. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.10.022 · Cited by 51
“Rapamycin, an mTOR inhibitor [9], dephosphorylates 4EBP1 and S6K1 by inhibiting mTORC1 phosphorylation of rictor, one of the proteins in the mTORC2 [10].”
Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 55
Cui, J., & Placzek, W. J. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.60 · Cited by 52
Zhang, T., Qu, S., Shi, Q., He, D., & Jin, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15023154 · Cited by 49
“Recent studies demonstrated that Mcl-1 could also be regulated at the translational level involved an mTOR/S6K1-dependent mechanism [32,33].”
Backgroundvan de Laar, L., Buitenhuis, M., Wensveen, F. M., Janssen, H. L. A., Coffer, P. J., & Woltman, A. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903089 · Cited by 54
“Although the regulation of these proteins by mTOR is at the translational level (47, 48), the reduced mRNA expression suggests a diminished role in survival regulation and thus a reduced requirement of mTOR mediated translational control of these proteins.”
Background
Metadata
- Authors
- Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., Kogan, S. C., Nadon, R., Housman, D. E., Lowe, S. W., & Pelletier, J.
- Affiliations
- *Department of Biochemistry,
- Cold Spring Harbor Laboratory (US)
- Memorial Sloan Kettering Cancer Center (US)
- Molecular Oncology Research Institute, 750 Washington Street, Tufts–New England Medical Center, Box 5609, Boston, MA 02111;
- Tufts University (US)
- University of California, San Francisco (US)
- McGill University and Génome Québec Innovation Centre (CA)
- Massachusetts Institute of Technology (US)
- Howard Hughes Medical Institute (US)
- McGill University (CA)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10853-10858
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504845
- OpenAlex
- W2024841712
- Cited by
- 285
- References
- 29
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 6 · 2023: 13 · 2022: 19 · 2021: 14 · 2020: 15 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 30 · 2014: 16 · 2013: 24 · 2012: 17
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- Brigham and Women's Hospital
- Canadian Breast Cancer Research Alliance
- National Institutes of Health (CA87497)
- Canadian Institutes of Health Research
- National Cancer Institute (CA-87497, P01CA087497, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTORC1, Mcl-1, translational regulation, TSC2, PI3K/Akt signaling, rapamycin, apoptosis, Eμ-Myc lymphoma, chemosensitivity, mTORC1 inhibitors, Bcl-2 family proteins, tumor cell survival
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Tuberous Sclerosis Complex 2 Protein, Animals, Lymphoma, Proteins, Transcription Factors, Immunoblotting, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-bcl-2, Sirolimus, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Multiprotein Complexes, Immunoprecipitation, Mice, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.